Skip to main content
Clinical Cardiology logoLink to Clinical Cardiology
. 2009 Feb 3;22(5):361–365. doi: 10.1002/clc.4960220513

Antianginal and anti‐ischemic effects of nisoldipine and ramipril in patients with syndrome X

Fatih Özçelik 1,, Armaǧan Altun 1, Gultaç Özbay 1
PMCID: PMC6656278  PMID: 10326170

Abstract

Background: Syndrome X is defined as typical angina pectoris, positive treadmill exercise test, negative intravenous ergonovine test, and angiographically normal coronary arteries.

Hypothesis: in the present study, we investigated the anti‐ischemic and antianginal effects of nisoldipine and ramipril in patients with syndrome X.

Methods: After 2 weeks of the first wash‐out period, 18 patients (7 men, 11 women, age 46 ± 10 years) were given nisoldipine (NIS) 5 mg twice daily for 4 weeks, and after 2 weeks of the second wash‐out period, the same patients were given ramipril (RAM) 2.5 mg once daily for 4 weeks. A treadmill exercise test with modified Bruce protocol was performed at the end of each period.

Results: The time to angina in exercise (607 ± 115 s‐650 ± 117 s, p = 0.006, vs. 630 ± 114 s‐660 ± 123 s, p = 0.02), total exercise time (612 ± 110 s‐656 ± 114 s, p = 0.0008, vs. 630 ± 114 s‐660 ± 123 s, p = 0.02), and maximum MET value (11.09 ± 2.08–11.86 ± 2.04, p = 0.0016, vs. 11.42 ± 2.09–12.2 ± 2.26, p = 0.01) were increased significantly with both therapy modalities. The time to 1 mm ST‐segment depression (123 ± 93 s ‐ 220 ± 172 s, p = 0.002) was increased significantly with NIS therapy. The time to ST‐segment recovery (434 ± 268 s‐330 ± 233 s, p = 0.016 vs. 443 ± 289 s‐370 ± 278 s, p = 0.012), the frequency of anginal attacks per week (1.27 ± 1.4–0 ± 0.38, p = 0.005, vs. 1 ± 1.32–0.33 ± 0.59, p = 0.028), and the need for sublingual nitroglycerin (1.16 ± 1.29–0.11 ± 0.32, p = 0.005, vs. 0.94 ± 1.16–0.27 ± 0.57, p = 0.012) were decreased significantly with both drugs.

Conclusion: We observed that 10 mg daily NIS and 2.5 mg daily RAM have similar anti‐ischemic and antianginal effects in patients with syndrome X.

Keywords: calcium‐channel blocker, angiotensin‐converting enzyme inhibitor, syndrome X

Full Text

The Full Text of this article is available as a PDF (524.9 KB).

References

  • 1. Maseri A, Crea F, Kaski JC, Crake T: Mechanisms of angina pectoris in syndrome X. J Am Coll Cardiol 1991; 17: 499–506 [DOI] [PubMed] [Google Scholar]
  • 2. Lanza GA, Manzoli A, Bia E, Crea F, Maseri A: Acute effects of nitrates on exercise testing in patients with syndrome X. Circulation 1994; 90: 2695–2700 [DOI] [PubMed] [Google Scholar]
  • 3. Cianflone D, Lanza GA, Maseri A: Microvascular angina in patients with normal coronary arteries and with other ischaemic syndromes. Eur Heart J 1995; 16 (suppl I): 96–103 [DOI] [PubMed] [Google Scholar]
  • 4. Cannon RO, Leon MB, Watson RM, Rosing DR, Epstein SE: Chest pain and normal coronary arteries. Role of small coronary arteries. Am J Cardiol 1986; 58: 53–59 [DOI] [PubMed] [Google Scholar]
  • 5. Cannon RO, Epstein SE: “Microvascular angina” as a cause of chest pain with angiographically normal coronary arteries. Am J Cardiol 1988; 61: 1338–1343 [DOI] [PubMed] [Google Scholar]
  • 6. Legrand V, Hodgson J, Bates ER, Aueron FM, Mancini GB, Smith JS, Gross MD, Vogel RA: Abnormal coronary flow reserve and abnormal radionuclide exercise test results in patients with normal coronary angiogram. J Am Coll Cardiol 1985; 6: 1245–1253 [DOI] [PubMed] [Google Scholar]
  • 7. Cannon RO, Bonaw R, Bacharach SL: Left ventricular dysfunction in patients with angina pectoris, normal epicardial coronary arteries and abnormal vasodilator reserve. Circulation 1985; 71: 218–226 [DOI] [PubMed] [Google Scholar]
  • 8. Tweddle AC, Martin W, Hutton I: Thallium scan in syndrome X. Br Heart J 1992; 68: 48–50 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 9. Bugiardini R, Borghi A, Biagetti L, Puddu P: Comparison of verapamil versus propranolol therapy in syndrome X. Am J Cardiol 1989; 63: 286–290 [DOI] [PubMed] [Google Scholar]
  • 10. Cannon RO, Watson RM, Rosing DR, Epstein SE: Efficacy of calcium channel blocker therapy for angina pectoris resulting from small‐vessel coronary disease and abnormal vasodilator reserve. Am J Cardiol 1985; 56: 242–246 [DOI] [PubMed] [Google Scholar]
  • 11. Cannon RO, Cunnion RE, Parrillo JE, Palmeri ST, Tucker EE, Schenke WH, Epstein SE: Dynamic limitation of coronary vasodilator reserve in patients with dilated cardiomyopathy and chest pain. J Am Coll Cardiol 1987; 10: 1190–1200 [DOI] [PubMed] [Google Scholar]
  • 12. Pupita G, Kaski JC, Galassi AR, Vejar M, Crea F, Maseri A: Long‐term variability of angina pectoris and electrocardiographic signs of ischemia in syndrome X. Am J Cardiol 1989; 64: 139–143 [DOI] [PubMed] [Google Scholar]
  • 13. Montorsi P, Cozzi S, Loaldi A, Fabbiocchi F, Annoni L, De Cesare N, Polese A, Guazzi MD: Acute coronary vasomotor effects of nifedipine and therapeutic correlates in syndrome X. Am J Cardiol 1990; 66: 302–307 [DOI] [PubMed] [Google Scholar]
  • 14. Likoff W, Segal BL, Kasparian H: Paradox of normal selective coronary angiograms in patients considered to have unmistakable coronary heart disease. N Engl J Med 1967; 276: 1063–1066 [DOI] [PubMed] [Google Scholar]
  • 15. Kemp HG, Vokonas PS, Cohn PF, Gorlin R: The anginal syndrome associated with normal coronary angiograms. Report of six years experience. Am J Med 1973; 54: 735–742 [DOI] [PubMed] [Google Scholar]
  • 16. Kashi JC, Rosano G, Gavrielides S, Chen L: Effects of angiotensin‐converting enzyme inhibition on exercise induced angina and ST segment depression in patients with microvascular angina. J Am Coll Cardiol 1994; 23: 652–657 [DOI] [PubMed] [Google Scholar]
  • 17. Cannon RO, Camici PG, Epstein SE: Pathophysiology dilemma of syndrome X. Circulation 1992; 85: 883–892 [DOI] [PubMed] [Google Scholar]
  • 18. Camici PG, Marraccini P, Lorenzoni R, Buzzigoli G, Pecori N, Perrissinotto A, Ferrannini E, L'Abbate A, Marzitti, M : Coronary hemodynamic and myocardial metabolism in patients with syndrome X: Response to pacing stress. J Am Coll Cardiol 1991; 17: 1461–1470 [DOI] [PubMed] [Google Scholar]
  • 19. Inobe Y, Kugiyama K, Morita E, Kawano H, Okumura K, Tomiguchi S, Tsuji A, Kojima A, Takahashi M, Yasue H: Role of adenosine in pathogenesis of syndrome X: Assessment with coronary hemodynamic measurements and thallium‐201 myocardial single‐photon emission computed tomography. J Am Coll Cardiol 1996; 28: 890–896 [DOI] [PubMed] [Google Scholar]
  • 20. Wiedermann JG, Schwartz A, Apfelbaum M: Anatomic and physiologic heterogeneity in patients with syndrome X: An intravascular ultrasound study. J Am Coll Cardiol 1995; 25: 1310–1317 [DOI] [PubMed] [Google Scholar]
  • 21. Dzau VJ: Implications of local angiotensin production in cardiovascular physiology and pharmacology. Am J Cardiol 1987; 59 (suppl A): 59A–65A [DOI] [PubMed] [Google Scholar]
  • 22. Nakashima A, Angus JA, Johnston CI: Chronotrophic effects of angiotensin I, angiotensin II, bradykinin and norepinephrine in guinea pig atria. Eur J Pharmacol 1982; 81: 479–485 [DOI] [PubMed] [Google Scholar]
  • 23. Fauter NO, Holmes JC: Coronary and myocardial action of angiotensin. Circ Res 1964; 14: 191–201 [DOI] [PubMed] [Google Scholar]
  • 24. Perondi R, Saino A, Tio RA, Pomidossi G, Gregorini L, Alessio P, Morganti A, Zanchetti A, Mancia G: ACE inhibition attenuates sympathetic coronary artery disease. Circulation 1992; 85: 2004–2013 [DOI] [PubMed] [Google Scholar]
  • 25. Kiowski W, Zuber M, Elsasser S, Erne P, Pfister M, Buckart F: Coronary vasodilation and improved myocardial lactate metabolism after ACE inhibitions with cilazapril in patients with congestive heart failure. Am Heart J 1991; 122: 1282–1388 [DOI] [PubMed] [Google Scholar]
  • 26. Altun A, Özkan B, Özçelik F, Altun G, Özbay G: Chronic sympathetic activation affects dispersion of ventricular repolarization in syndrome X. Proceedings of EUROPACE ′97, Eighth European Symposium on Cardiac Pacing, p. 155–158. Bologna: Monduzzi Editore, S.p.A., 1997. [Google Scholar]

Articles from Clinical Cardiology are provided here courtesy of Wiley

RESOURCES